MEDRES-MEDICAL RESEARCH GMBH

Their core work

MEDRES is a Cologne-based private SME specializing in advanced medical imaging technologies, particularly 19F magnetic resonance imaging (MRI) using perfluorocarbon-based nanomaterials. They contribute preclinical and translational research expertise to EU consortia focused on molecular imaging, image-guided surgery, and nanoparticle-based therapeutic interventions. Their work spans from cancer immunotherapy imaging to chronic pain diagnostics, bridging the gap between imaging science and clinical application.

What they specialise in

How they've shifted over time

MEDRES started with cancer-focused work — image-guided surgery (ISPIC, 2016) and personalized immunotherapy (CANCER, 2018), emphasizing less invasive treatment approaches. From 2020 onward, their focus shifted decisively toward 19F MRI and perfluorocarbon nanomaterials, with three consecutive projects (NOVA-MRI, SENATOR, PIANO) building deep capability in this niche. The latest project (PIANO, 2021) signals a further expansion into chronic pain diagnostics, applying their imaging expertise to a new therapeutic domain.

MEDRES is consolidating around 19F MRI as a core platform technology and expanding its application from oncology into pain medicine and neuroscience.

How they like to work

MEDRES exclusively participates as a partner — never as coordinator — suggesting they contribute specialized technical expertise rather than managing large consortia. With 37 unique partners across 9 countries from just 5 projects, they operate in medium-to-large international consortia and appear to be a sought-after specialist. Their consistent MSCA funding (both ITN training networks and RISE staff exchanges) indicates they actively host and exchange researchers, making them an accessible and collaborative partner.

MEDRES has built a network of 37 consortium partners across 9 countries through 5 projects, indicating broad European connections relative to their size. As a German SME in MSCA networks, they likely connect with universities and research hospitals across Western and Southern Europe.

What sets them apart

MEDRES occupies a rare niche as a private SME with deep expertise in 19F MRI — a specialized imaging modality that most companies and even many universities cannot offer. Their combination of nanomaterial development, perfluorocarbon chemistry, and preclinical imaging makes them a natural partner for any consortium needing non-proton MRI capabilities. For consortium builders, they bring industry-perspective to academic imaging projects, which strengthens impact narratives and commercialization pathways.

Highlights from their portfolio

• NOVA-MRI
  Their largest-funded project (EUR 252,788) and the clearest expression of their core 19F MRI expertise, focused on developing new applications for fluorine-based magnetic resonance imaging.
• PIANO
  Represents a strategic expansion into chronic pain diagnostics using nanoparticle imaging — a new application domain that could open significant commercial opportunities.
• ISPIC
  Their earliest H2020 project, combining image-guided surgery with immunotherapy — an ambitious intersection that seeded their later imaging specialization.